Clinical Trials Logo
  1. Home
  2. Pre-hypertension
  3. NCT00553969

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease — DETECT  

Pre-hypertension Clinical Trial

Official title:
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)

Clinical Trial Summary

This study will examine the individual and combined effects of Coreg CR and lisinopril, on cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo controlled comparison over a 9-month study period. Patients to be randomized will have pre-hypertensive blood pressures that do not require anti-hypertensive therapy and at least one additional cardiovascular risk factor.

Clinical Trial Description

- This study will compare the effect of Coreg CR and lisinopril, separately and together, on Rasmussen Disease Score in a controlled study with an inactive substance (placebo).

- Study patients will have pre-hypertensive (slightly elevated) blood pressures not requiring therapy.

- Lisinopril is an angiotensin converting enzyme (ACE) inhibitor. Angiotensin is a chemical that is made by the body continuously. Angiotensin narrows blood vessels and thereby maintains (elevates) blood pressure. When the enzyme is blocked by lisinopril, angiotensin cannot be converted into its active form. As a result, blood pressure is lowered. Lisinopril is a drug that has been approved for use by the U.S. Food and Drug Administration (FDA) and health authorities for the treatment of high blood pressure and heart failure.

- Coreg CR is a once-a-day heart medication that is part of a class of drugs known as beta-blockers. Beta-blockers prevent beta-adrenergic substances such as adrenaline from activating parts of the nervous system, including the heart. Beta-blockers therefore relieve stress on the heart by slowing heart beat, decreasing the force of heart muscle contractions, and reducing blood pressure. Coreg has also been approved by the FDA for the treatment of hypertension and various other cardiovascular conditions.

- It is possible that the beta blocker could increase the benefits of the ACE inhibitor by inhibiting renin production, which is an important step in angiotensin production. These two drugs may act together to provide even more protection to blood vessels and the heart. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00553969
Study type Interventional
Source University of Minnesota - Clinical and Translational Science Institute
Contact
Status Completed
Phase Phase 1/Phase 2
Start date November 2007
Completion date December 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT03313284 - Respiratory Muscle Training and Intermittent Hypoxia: Additive Health Effects? N/A
Completed NCT01741779 - Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function N/A
Withdrawn NCT01074918 - Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients Phase 1/Phase 2
Completed NCT00288158 - Primary Prevention of Hypertension in Obese Adolescents Phase 2
Completed NCT01190319 - Study: Effects of Strawberries on Blood Pressure N/A
Completed NCT01008176 - Restoring Sleep Homeostasis to Lower Blood Pressure N/A
Unknown status NCT02197910 - Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects N/A
Recruiting NCT04543656 - Personalized Blood Pressure Care Using IoMTs and Artificial Intelligence N/A
Completed NCT03168789 - Tension Tamer Randomized Control Trial N/A
Completed NCT00170937 - A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome Phase 4
Completed NCT01741766 - The Effects of Stretching Training on Arterial Function and Autonomic Control N/A
Completed NCT02143817 - Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition N/A
Terminated NCT00388388 - Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects Phase 2
Completed NCT02148458 - Short Term Intermittent Fasting and Mediterranean Diet N/A
Terminated NCT01349114 - Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects Phase 4
Completed NCT02038179 - Center of Research Translation (CORT) Project 2 Phase 2/Phase 3
Completed NCT00970931 - Hypertension Prevention in Pre-Hypertensive Individuals Phase 3
Completed NCT01202175 - Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension Phase 4
Not yet recruiting NCT01364675 - Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects N/A
Completed NCT01841840 - The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke N/A